Molbio Diagnostics IPO Preview: Subscription 10 August 2026 to 12 August 2026 : Key Details, Price Band and Investment Analysis

August 6, 2026
Posted by: Ankit Jaiswal
Category: IPO

Molbio Diagnostics IPO subscription 10 August 2026 to 12 August 2026. Healthcare and Molecular Diagnostics sector. Check NSE/BSE for price band, lot size and DRHP.

The Molbio Diagnostics IPO is set to open for public subscription on 10 August 2026, with the issue running from 10 August 2026 to 12 August 2026. Molbio Diagnostics is a Healthcare and Molecular Diagnostics company that has filed its Draft Red Herring Prospectus (DRHP) with SEBI to raise capital through this initial public offering. The Molbio Diagnostics IPO has attracted investor interest ahead of its subscription window, and investors looking to apply should review the DRHP available on nseindia.com and bseindia.com for complete details on financials, promoter background, and risk factors specific to the Molbio Diagnostics IPO.

Click Here – Get Free Investment Predictions

Table of Contents

Molbio Diagnostics IPO: Company Overview

Molbio Diagnostics is a healthcare company known for its molecular diagnostic technology, including the Truenat platform that provides rapid, point-of-care molecular testing for tuberculosis, COVID-19, and other infectious diseases. The company has established a strong domestic and international footprint in molecular diagnostics and is raising capital through the Molbio Diagnostics IPO to fund growth and expansion. The Molbio Diagnostics IPO aims to raise capital that will be utilised as described in the official DRHP filed with SEBI. Investors should refer to the official DRHP for the complete use of proceeds and business financials of the Molbio Diagnostics IPO.

Molbio Diagnostics IPO Key Details

Detail	Information
IPO Name	Molbio Diagnostics IPO
Open Date	10 August 2026
Close Date	12 August 2026
Price Band	Check nseindia.com or bseindia.com
Lot Size	Check nseindia.com or bseindia.com
Sector	Healthcare and Molecular Diagnostics
Issue Type	Book Built Issue
Allotment (est.)	Approx. 2-3 days after close

Track Molbio Diagnostics IPO on the Univest Screener

Should You Apply for the Molbio Diagnostics IPO?

The decision to apply for the Molbio Diagnostics IPO should be based on a thorough review of the company financials, competitive positioning in the Healthcare and Molecular Diagnostics space, valuations relative to listed peers, and your personal risk appetite. Investors are strongly encouraged to read the official DRHP available on nseindia.com and bseindia.com before applying to the Molbio Diagnostics IPO. The DRHP contains complete information on financials, risk factors, and use of IPO proceeds.

The Molbio Diagnostics IPO should also be evaluated in the context of overall market conditions on the subscription date. The Nifty 50 direction and broader market sentiment can influence IPO demand and the eventual listing performance of the Molbio Diagnostics IPO.

Grey Market Premium: What the Unofficial Market Says

Some investors track the grey market premium (GMP) as an informal demand indicator before a listing. It is critical to understand that GMP is not an official metric and is not regulated or endorsed by SEBI, NSE, or BSE. GMP figures can change rapidly and do not guarantee the actual listing price. Stocks have listed at, above, or significantly below the grey market premium depending on market conditions. For indicative grey market data, refer to third-party platforms such as InvestorGain.com or Chittorgarh.com. Always base investment decisions on the official prospectus and company fundamentals.

How to Apply for the Molbio Diagnostics IPO

To apply for the Molbio Diagnostics IPO, you need an active Demat account with a SEBI-registered broker. When the Molbio Diagnostics IPO opens on 10 August 2026, navigate to the IPO section on your broker platform, select the Molbio Diagnostics IPO, enter your bid price within the price band and the number of lots, and approve the UPI mandate for ASBA. Bids must be placed before the Molbio Diagnostics IPO closes on 12 August 2026.

Download the Univest iOS App or Univest Android App to apply for the Molbio Diagnostics IPO and get upcoming IPO alerts.

Conclusion

The Molbio Diagnostics IPO opens on 10 August 2026 and closes on 12 August 2026, giving investors in the Healthcare and Molecular Diagnostics segment a window to participate. The This public offer should be evaluated against the company DRHP available on nseindia.com before applying. Investors should assess the The issue price band, lot size, and company fundamentals before making a subscription decision.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all IPO details including price band, lot size, and subscription data with the official NSE (nseindia.com) and BSE (bseindia.com) websites and the company DRHP before making any investment decision. Investments in IPOs are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

Frequently Asked Questions

When does the The subscription open?

Ans. The The listing opens on 10 August 2026 and closes on 12 August 2026. The The offering subscription window runs for this period.

What is the This public offer price band?

Ans. The The issue price band is available on the official NSE (nseindia.com) and BSE (bseindia.com) websites and in the DRHP. Always verify the The subscription price band from official sources before applying.

What is the The listing lot size?

Ans. The The offering lot size is disclosed in the official prospectus available on nseindia.com and bseindia.com. Check these portals for the minimum lot size required to apply for the This public offer.

How do I apply for the The issue?

Ans. Apply for the The subscription through your SEBI-registered broker or UPI-enabled app from 10 August 2026. Select the The listing, enter your lot count and bid price, and approve the UPI ASBA mandate. The The offering closes on 12 August 2026.

What is the This public offer allotment date?

Ans. The The issue allotment is expected approximately 2-3 trading days after the subscription closes on 12 August 2026. The confirmed The subscription allotment date will be announced on NSE and BSE portals.

What is the grey market premium for The listing?

Ans. Grey market premium data for the The offering is unofficial and not regulated by SEBI, NSE, or BSE. For indicative grey market data on the This public offer, check InvestorGain.com or Chittorgarh.com. This does not predict the actual The issue listing price.

News

Author: Ankit Jaiswal

Ankit Jaiswal is the Senior Research Analyst at Univest, leading the platform's in-house equity research desk and serving as the editorial reviewer for all research and blog content published at univest.in. With 11+ years of experience in Indian equity markets, he oversees stock recommendations, earnings analysis, sector coverage, and ensures every published article meets SEBI Research Analyst Regulations. He holds a Bachelor of Commerce (B.Com) from St. Xavier's College, Kolkata — one of India's most prestigious commerce institutions — and has cleared CMT Level 2 from the CMT Association, a globally recognised certification in technical analysis and market research. His research methodology combines fundamental analysis (earnings quality, balance sheet strength, management commentary) with advanced technical analysis (chart patterns, momentum indicators, market structure) — giving Univest's retail investors a dual-lens approach that most Indian research platforms lack. Ankit is among the most comprehensively certified analysts in Indian financial media, holding five NISM certifications: Series-XV (Research Analyst), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-VI (Depository Operations), and Series-V-A (Mutual Fund Distributors). At Univest — India's SEBI-registered research and advisory platform — Ankit's responsibilities include leading the research team, finalising stock recommendations published across Pro Lite, Pro Super, and Pro Gold advisory services, and maintaining editorial oversight of all YMYL financial content published on the blog.